-
Sanjin Pharma’s Subsidiary Gets NMPA Nod for BC007 Cancer Study
•
China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Biopharmaceutical (Shanghai) Co., Ltd, has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study of BC007. The study will assess the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor efficacy…
-
Sanjin Pharma’s Subsidiary Gets FDA Nod for BC007 Cancer Drug Trial
•
China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Pharmaceutical (Shanghai) Co., Ltd, has received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase I clinical study of BC007, a bispecific antibody (BsAb) targeting CLDN18.2 and CD47, in patients with solid…
